1559 related articles for article (PubMed ID: 33761207)
1. Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.
Bieber T; Simpson EL; Silverberg JI; Thaçi D; Paul C; Pink AE; Kataoka Y; Chu CY; DiBonaventura M; Rojo R; Antinew J; Ionita I; Sinclair R; Forman S; Zdybski J; Biswas P; Malhotra B; Zhang F; Valdez H;
N Engl J Med; 2021 Mar; 384(12):1101-1112. PubMed ID: 33761207
[TBL] [Abstract][Full Text] [Related]
2. Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial.
Ständer S; Kwatra SG; Silverberg JI; Simpson EL; Thyssen JP; Yosipovitch G; Zhang F; Cameron MC; Cella RR; Valdez H; DiBonaventura M; Feeney C
Am J Clin Dermatol; 2023 Jan; 24(1):97-107. PubMed ID: 36512175
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial.
Simpson EL; Silverberg JI; Thyssen JP; Viguier M; Thaçi D; de Bruin-Weller M; Weidinger S; Chan G; DiBonaventura M; Biswas P; Feeney C; Koulias C; Cork MJ
Am J Clin Dermatol; 2023 Jul; 24(4):609-621. PubMed ID: 37213005
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Simpson EL; Sinclair R; Forman S; Wollenberg A; Aschoff R; Cork M; Bieber T; Thyssen JP; Yosipovitch G; Flohr C; Magnolo N; Maari C; Feeney C; Biswas P; Tatulych S; Valdez H; Rojo R
Lancet; 2020 Jul; 396(10246):255-266. PubMed ID: 32711801
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Phase 2 Randomized Clinical Trial.
Gooderham MJ; Forman SB; Bissonnette R; Beebe JS; Zhang W; Banfield C; Zhu L; Papacharalambous J; Vincent MS; Peeva E
JAMA Dermatol; 2019 Dec; 155(12):1371-1379. PubMed ID: 31577341
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.
Silverberg JI; Simpson EL; Thyssen JP; Gooderham M; Chan G; Feeney C; Biswas P; Valdez H; DiBonaventura M; Nduaka C; Rojo R
JAMA Dermatol; 2020 Aug; 156(8):863-873. PubMed ID: 32492087
[TBL] [Abstract][Full Text] [Related]
7. Magnitude and Time Course of Response to Abrocitinib for Moderate-to-Severe Atopic Dermatitis.
Reich K; Lio PA; Bissonnette R; Alexis AF; Lebwohl MG; Pink AE; Kabashima K; Boguniewicz M; Nowicki RJ; Valdez H; Zhang F; DiBonaventura M; Cameron MC; Clibborn C
J Allergy Clin Immunol Pract; 2022 Dec; 10(12):3228-3237.e2. PubMed ID: 36108923
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial.
Reich K; Thyssen JP; Blauvelt A; Eyerich K; Soong W; Rice ZP; Hong HC; Katoh N; Valenzuela F; DiBonaventura M; Bratt TA; Zhang F; Clibborn C; Rojo R; Valdez H; Kerkmann U
Lancet; 2022 Jul; 400(10348):273-282. PubMed ID: 35871814
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis: The JADE TEEN Randomized Clinical Trial.
Eichenfield LF; Flohr C; Sidbury R; Siegfried E; Szalai Z; Galus R; Yao Z; Takahashi H; Barbarot S; Feeney C; Zhang F; DiBonaventura M; Rojo R; Valdez H; Chan G
JAMA Dermatol; 2021 Oct; 157(10):1165-1173. PubMed ID: 34406366
[TBL] [Abstract][Full Text] [Related]
10. Phase 3 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab (JADE EXTEND).
Shi VY; Bhutani T; Fonacier L; Deleuran M; Shumack S; Valdez H; Zhang F; Chan GL; Cameron MC; Yin NC
J Am Acad Dermatol; 2022 Aug; 87(2):351-358. PubMed ID: 35439608
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial.
Thaçi D; Simpson EL; Beck LA; Bieber T; Blauvelt A; Papp K; Soong W; Worm M; Szepietowski JC; Sofen H; Kawashima M; Wu R; Weinstein SP; Graham NM; Pirozzi G; Teper A; Sutherland ER; Mastey V; Stahl N; Yancopoulos GD; Ardeleanu M
Lancet; 2016 Jan; 387(10013):40-52. PubMed ID: 26454361
[TBL] [Abstract][Full Text] [Related]
12. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.
Beck LA; Thaçi D; Hamilton JD; Graham NM; Bieber T; Rocklin R; Ming JE; Ren H; Kao R; Simpson E; Ardeleanu M; Weinstein SP; Pirozzi G; Guttman-Yassky E; Suárez-Fariñas M; Hager MD; Stahl N; Yancopoulos GD; Radin AR
N Engl J Med; 2014 Jul; 371(2):130-9. PubMed ID: 25006719
[TBL] [Abstract][Full Text] [Related]
13. Switching between JAK Inhibitors in Patients with Atopic Dermatitis: Unanswered Questions in Daily Clinical Practice.
Mastraftsi S; Bakakis M; Tsiogka A; Afroditi Kleidona I; Gregoriou S
Acta Dermatovenerol Croat; 2023 Dec; 31(3):162-164. PubMed ID: 38439732
[TBL] [Abstract][Full Text] [Related]
14. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
Blauvelt A; de Bruin-Weller M; Gooderham M; Cather JC; Weisman J; Pariser D; Simpson EL; Papp KA; Hong HC; Rubel D; Foley P; Prens E; Griffiths CEM; Etoh T; Pinto PH; Pujol RM; Szepietowski JC; Ettler K; Kemény L; Zhu X; Akinlade B; Hultsch T; Mastey V; Gadkari A; Eckert L; Amin N; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Shumel B
Lancet; 2017 Jun; 389(10086):2287-2303. PubMed ID: 28478972
[TBL] [Abstract][Full Text] [Related]
15. Rapidity of Improvement in Signs/Symptoms of Moderate-to-Severe Atopic Dermatitis by Body Region with Abrocitinib in the Phase 3 JADE COMPARE Study.
Alexis A; de Bruin-Weller M; Weidinger S; Soong W; Barbarot S; Ionita I; Zhang F; Valdez H; Clibborn C; Yin N
Dermatol Ther (Heidelb); 2022 Mar; 12(3):771-785. PubMed ID: 35297025
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Reich K; Teixeira HD; de Bruin-Weller M; Bieber T; Soong W; Kabashima K; Werfel T; Zeng J; Huang X; Hu X; Hendrickson BA; Ladizinski B; Chu AD; Silverberg JI
Lancet; 2021 Jun; 397(10290):2169-2181. PubMed ID: 34023009
[TBL] [Abstract][Full Text] [Related]
17. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.
Simpson EL; Bieber T; Guttman-Yassky E; Beck LA; Blauvelt A; Cork MJ; Silverberg JI; Deleuran M; Kataoka Y; Lacour JP; Kingo K; Worm M; Poulin Y; Wollenberg A; Soo Y; Graham NM; Pirozzi G; Akinlade B; Staudinger H; Mastey V; Eckert L; Gadkari A; Stahl N; Yancopoulos GD; Ardeleanu M;
N Engl J Med; 2016 Dec; 375(24):2335-2348. PubMed ID: 27690741
[TBL] [Abstract][Full Text] [Related]
18. Patient-reported outcomes from the JADE COMPARE randomized phase 3 study of abrocitinib in adults with moderate-to-severe atopic dermatitis.
Thyssen JP; Yosipovitch G; Paul C; Kwatra SG; Chu CY; DiBonaventura M; Feeney C; Zhang F; Myers D; Rojo R; Valdez H
J Eur Acad Dermatol Venereol; 2022 Mar; 36(3):434-443. PubMed ID: 34779063
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Dupilumab Treatment with Concomitant Topical Corticosteroids in Children Aged 6 Months to 5 Years with Severe Atopic Dermatitis.
Paller AS; Pinter A; Wine Lee L; Aschoff R; Zdybski J; Schnopp C; Praestgaard A; Bansal A; Shumel B; Prescilla R; Bastian M
Adv Ther; 2024 Mar; 41(3):1046-1061. PubMed ID: 38194047
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial.
Simpson EL; Paller AS; Siegfried EC; Boguniewicz M; Sher L; Gooderham MJ; Beck LA; Guttman-Yassky E; Pariser D; Blauvelt A; Weisman J; Lockshin B; Hultsch T; Zhang Q; Kamal MA; Davis JD; Akinlade B; Staudinger H; Hamilton JD; Graham NMH; Pirozzi G; Gadkari A; Eckert L; Stahl N; Yancopoulos GD; Ruddy M; Bansal A
JAMA Dermatol; 2020 Jan; 156(1):44-56. PubMed ID: 31693077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
